New hope for GBS: Single-Dose drug enters final testing
Disease control
Recruiting now
This study tests a single dose of tanruprubart (ANX005) in 30 adults and children with Guillain-Barré syndrome (GBS), a rare nerve disorder that causes weakness. The goal is to see how the drug works in the body, its early effects, and its safety. Participants must have GBS sympt…
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC